• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

自体骨髓来源的单核细胞移植治疗不可治愈的神经发育障碍和损伤的儿童是安全的,并能提高他们的生活质量。

Administration of autologous bone marrow-derived mononuclear cells in children with incurable neurological disorders and injury is safe and improves their quality of life.

机构信息

Department of Medical Services and Clinical Research, NeuroGen Brain and Spine Institute, Surana Sethia Hospital and Research Centre, Mumbai, India.

出版信息

Cell Transplant. 2012;21 Suppl 1:S79-90. doi: 10.3727/096368912X633798.

DOI:10.3727/096368912X633798
PMID:22507683
Abstract

Neurological disorders such as muscular dystrophy, cerebral palsy, and injury to the brain and spine currently have no known definitive treatments or cures. A study was carried out on 71 children suffering from such incurable neurological disorders and injury. They were intrathecally and intramuscularly administered autologous bone marrow-derived mononuclear cells. Assessment after transplantation showed neurological improvements in muscle power and a shift on assessment scales such as FIM and Brooke and Vignos scale. Further, imaging and electrophysiological studies also showed significant changes in selective cases. On an average follow-up of 15 ± 1 months, overall 97% muscular dystrophy cases showed subjective and functional improvement, with 2 of them also showing changes on MRI and 3 on EMG. One hundred percent of the spinal cord injury cases showed improvement with respect to muscle strength, urine control, spasticity, etc. Eighty-five percent of cases of cerebral palsy cases showed improvements, out of which 75% reported improvement in muscle tone and 50% in speech among other symptoms. Eighty-eight percent of cases of other incurable neurological disorders such as autism, Retts Syndrome, giant axonal neuropathy, etc., also showed improvement. No significant adverse events were noted. The results show that this treatment is safe, efficacious, and also improves the quality of life of children with incurable neurological disorders and injury.

摘要

目前,神经紊乱疾病(如肌肉萎缩症、脑瘫以及脑和脊柱损伤)尚无明确的治疗方法或治愈方法。本研究对 71 名患有此类不治之症和损伤的儿童进行了研究。对他们进行了鞘内和肌肉内注射自体骨髓来源的单核细胞治疗。移植后的评估显示,肌肉力量的神经功能得到改善,FIM 和 Brooke 和 Vignos 量表等评估量表也发生了转变。此外,影像学和电生理学研究也显示在某些选择性病例中有明显的变化。平均随访 15±1 个月后,97%的肌肉萎缩症病例表现出主观和功能改善,其中 2 例 MRI 发生变化,3 例 EMG 发生变化。100%的脊髓损伤病例在肌肉力量、尿控制、痉挛等方面均有改善。85%的脑瘫病例有所改善,其中 75%的病例报告肌肉张力改善,50%的病例报告言语改善等症状。88%的其他不治之症的神经紊乱病例(如自闭症、雷特综合征、巨大轴突神经病等)也有改善。未观察到明显的不良事件。结果表明,这种治疗方法安全有效,还能提高患有不治之症的神经紊乱和损伤的儿童的生活质量。

相似文献

1
Administration of autologous bone marrow-derived mononuclear cells in children with incurable neurological disorders and injury is safe and improves their quality of life.自体骨髓来源的单核细胞移植治疗不可治愈的神经发育障碍和损伤的儿童是安全的,并能提高他们的生活质量。
Cell Transplant. 2012;21 Suppl 1:S79-90. doi: 10.3727/096368912X633798.
2
A clinical study shows safety and efficacy of autologous bone marrow mononuclear cell therapy to improve quality of life in muscular dystrophy patients.一项临床研究表明,自体骨髓单核细胞治疗可提高肌肉萎缩症患者的生活质量,且安全性和有效性良好。
Cell Transplant. 2013;22 Suppl 1:S127-38. doi: 10.3727/096368913X672136. Epub 2013 Sep 10.
3
Autologous bone marrow derived mononuclear cell therapy for spinal cord injury: A phase I/II clinical safety and primary efficacy data.自体骨髓来源的单核细胞治疗脊髓损伤:一项I/II期临床安全性和主要疗效数据。
Exp Clin Transplant. 2009 Dec;7(4):241-8.
4
[Functional improvement of patients with progressive muscular dystrophy by bone marrow and umbilical cord blood mesenchymal stem cell transplantations].[骨髓和脐带血间充质干细胞移植对进行性肌营养不良患者的功能改善作用]
Zhonghua Yi Xue Za Zhi. 2009 Sep 29;89(36):2552-6.
5
An observational study of autologous bone marrow-derived stem cells transplantation in seven patients with nervous system diseases: a 2-year follow-up.自体骨髓源性干细胞移植治疗神经系统疾病 7 例的观察性研究:2 年随访。
Cell Biochem Biophys. 2014 May;69(1):179-87. doi: 10.1007/s12013-013-9756-8.
6
Administration of autologous bone marrow stem cells into spinal cord injury patients via multiple routes is safe and improves their quality of life: comprehensive case studies.通过多种途径将自体骨髓干细胞给予脊髓损伤患者是安全的,并能改善其生活质量:综合病例研究。
Cell Transplant. 2008;17(12):1277-93. doi: 10.3727/096368908787648074.
7
[Middle-term outcome of autologous bone marrow mononuclear cells transplantation for treatment of lower limb ischemia].自体骨髓单个核细胞移植治疗下肢缺血的中期结果
Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2009 Mar;23(3):341-4.
8
A comparison of autologous and allogenic bone marrow-derived mesenchymal stem cell transplantation in canine spinal cord injury.自体和同种异体骨髓间充质干细胞移植治疗犬脊髓损伤的比较。
J Neurol Sci. 2009 Oct 15;285(1-2):67-77. doi: 10.1016/j.jns.2009.05.027. Epub 2009 Jun 24.
9
Intramyocardial administration of autologous bone marrow mononuclear cells in a critically ill child with dilated cardiomyopathy.对一名患有扩张型心肌病的危重症儿童进行自体骨髓单个核细胞心肌内注射。
Cardiol Young. 2011 Feb;21(1):110-2. doi: 10.1017/S1047951110001435. Epub 2010 Oct 27.
10
Administration of ex vivo-expanded bone marrow-derived endothelial progenitor cells attenuates focal cerebral ischemia-reperfusion injury in rats.给予经体外扩增的骨髓源性内皮祖细胞可减轻大鼠局灶性脑缺血再灌注损伤。
Neurosurgery. 2006 Sep;59(3):679-86; discussion 679-86. doi: 10.1227/01.NEU.0000229058.08706.88.

引用本文的文献

1
Safety and Efficacy of Autologous Bone Marrow Derived Mononuclear Cell Transplant in the Management of Various Neurological Disorders.自体骨髓来源的单个核细胞移植治疗各种神经系统疾病的安全性和有效性
Cureus. 2024 Dec 12;16(12):e75617. doi: 10.7759/cureus.75617. eCollection 2024 Dec.
2
Stem cell therapy approaches for non-malignant diseases & non-haematological diseases in India: A systematic review.印度针对非恶性疾病和非血液学疾病的干细胞治疗方法:一项系统综述。
Indian J Med Res. 2024 Nov;160(5):411-427. doi: 10.25259/ijmr_2141_23.
3
A systematic review of cell therapy modalities and outcomes in cerebral palsy.
脑性瘫痪细胞治疗方式及结果的系统评价
Mol Cell Biochem. 2025 Feb;480(2):891-922. doi: 10.1007/s11010-024-05072-3. Epub 2024 Jul 21.
4
Adverse events of cell therapy clinical trials in human chronic spinal cord injury, a systematic review and meta-analysis.人类慢性脊髓损伤细胞治疗临床试验的不良事件:一项系统评价与荟萃分析
Regen Ther. 2024 Apr 22;27:381-397. doi: 10.1016/j.reth.2024.03.012. eCollection 2024 Dec.
5
Cell Therapy Strategies on Duchenne Muscular Dystrophy: A Systematic Review of Clinical Applications.细胞治疗策略在杜氏肌营养不良症中的应用:临床应用的系统评价。
Stem Cell Rev Rep. 2024 Jan;20(1):138-158. doi: 10.1007/s12015-023-10653-8. Epub 2023 Nov 13.
6
Innovations in cell therapy in pediatric diseases: a narrative review.儿科疾病细胞治疗的创新:一项叙述性综述。
Transl Pediatr. 2023 Jun 30;12(6):1239-1257. doi: 10.21037/tp-23-92. Epub 2023 Jun 9.
7
Outcomes of autologous bone marrow mononuclear cell administration in the treatment of neurologic sequelae in children with spina bifida.自体骨髓单个核细胞移植治疗小儿脊膜膨出神经后遗症的疗效观察。
Stem Cell Res Ther. 2023 Apr 28;14(1):115. doi: 10.1186/s13287-023-03349-w.
8
The density of bone marrow mononuclear cells and CD34+ cells in patients with three neurologic conditions.三种神经疾病患者骨髓单个核细胞和 CD34+细胞的密度。
BMC Neurol. 2023 Jan 23;23(1):37. doi: 10.1186/s12883-023-03071-3.
9
Immune response following traumatic spinal cord injury: Pathophysiology and therapies.创伤性脊髓损伤后的免疫反应:病理生理学和治疗方法。
Front Immunol. 2023 Jan 6;13:1084101. doi: 10.3389/fimmu.2022.1084101. eCollection 2022.
10
Autologous cellular therapy for cerebral palsy: a randomized, crossover trial.用于治疗脑瘫的自体细胞疗法:一项随机交叉试验。
Brain Commun. 2022 May 20;4(3):fcac131. doi: 10.1093/braincomms/fcac131. eCollection 2022.